Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251719 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
A Phase 3 study of Esophagitis, Reflux and Esophagitis, Peptic, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,054
- Enrollment target
- 20
- Study locations
NCT00251719 is a Phase 3 study of Esophagitis, Reflux and Esophagitis, Peptic that has completed, run by Takeda. The registered enrollment target is 2,054 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT00251719, a Phase 3 study of Esophagitis, Reflux and Esophagitis, Peptic, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,054 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically proven erosive esophagitis.
Conditions Studied
Interventions
- DRUG Lansoprazole
- DRUG Dexlansoprazole MR
Study Locations (20)
California
- - Azusa
- - Carmichael
- - Cypress
- - Fresno
- - Los Angeles
- - Modesto
- - Newport Beach
- - Oakland
- - Orange
- - San Diego
- - Santa Maria
Alabama
- - Anniston
- - Hueytown
- - Huntsville
- - Tallassee
- - Tuscaloosa
Arkansas
- - Little Rock
- - North Little Rock
Arizona
- - Tucson
Colorado
- - Littleton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,054 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251719
The ClinicalTrials.gov registry entry for NCT00251719 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,054 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Esophagitis, Reflux appearing as the primary indexed condition, and to 2 interventions - of which Lansoprazole is the first listed.
NCT00251719 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00251719 about?
NCT00251719 is a clinical study titled "Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis". This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically proven erosive esophagitis.
What is the current status of trial NCT00251719?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,054 participants. The study started on 2005-12. Estimated completion is 2007-01.
What conditions does trial NCT00251719 study?
This clinical trial studies the following conditions: Esophagitis, Reflux, Esophagitis, Peptic.
What interventions are being tested in trial NCT00251719?
The interventions under investigation include: Lansoprazole (DRUG), Dexlansoprazole MR (DRUG).
Who is sponsoring clinical trial NCT00251719?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00251719 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophagitis, Reflux
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.